2023
Association Between COVID-19 Infection and Pulmonary Fibrosis: A Nested Case-Control Study
Najjar-Debbiny R, Barnett-Griness O, Khoury J, Gronich N, Weber G, Adir Y, Shteinberg M, Shneir S, Sharma L, Saliba W. Association Between COVID-19 Infection and Pulmonary Fibrosis: A Nested Case-Control Study. The American Journal Of Medicine 2023, 136: 1087-1093.e2. PMID: 37598922, DOI: 10.1016/j.amjmed.2023.07.020.Peer-Reviewed Original ResearchPulmonary fibrosisCase-control studyCOVID-19 severityCOVID-19Multivariable conditional logistic regression modelsNested Case-Control StudyConditional logistic regression modelsSevere COVID-19Prior COVID-19COVID-19 infectionLogistic regression modelsLargest healthcare providerUnderlying cohortCohort entrySignificant morbiditySurveillance biasOdds ratioSevere diseaseFibrosisHealthcare providersCoronavirus diseaseCalendar timePatientsCohortLag time
2022
Effectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis
Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, Goldstein L, Saliba W. Effectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis. Clinical Infectious Diseases 2022, 76: 453-460. PMID: 36130189, DOI: 10.1093/cid/ciac781.Peer-Reviewed Original ResearchConceptsSevere COVID-19Composite outcomeSevere acute respiratory syndrome coronavirus 2COVID-19-specific mortalityModerate coronavirus disease 2019Acute respiratory syndrome coronavirus 2Propensity Score Matched AnalysisCOVID-19-related mortalityCOVID-19Respiratory syndrome coronavirus 2High-risk patientsTreatment of mildSyndrome coronavirus 2Emergency use authorizationCoronavirus disease 2019Largest healthcare providerHazard ratioVaccination statusMatched AnalysisCoronavirus 2Subgroup analysisDisease 2019High riskPositive testPatientsAwake endoscopic (esophageal) ultrasound using the endobronchial scope (EUS-B) for patients with high risk for sedation
Khoury J, Adir Y, Schneer S, Qdah M, Hakrush O, Abramovich A. Awake endoscopic (esophageal) ultrasound using the endobronchial scope (EUS-B) for patients with high risk for sedation. Respiratory Medicine And Research 2022, 82: 100944. PMID: 35878568, DOI: 10.1016/j.resmer.2022.100944.Peer-Reviewed Original Research
2021
Direct antiviral agents for chronic hepatitis C virus infection improve health-related quality of life significantly in the long term
Atamla M, Khoury J, Dabbah I, Kramsky R, Yaacob A, Veitsman E, Saadi T. Direct antiviral agents for chronic hepatitis C virus infection improve health-related quality of life significantly in the long term. Clinical And Experimental Hepatology 2021, 7: 258-263. PMID: 34712826, PMCID: PMC8527337, DOI: 10.5114/ceh.2021.109192.Peer-Reviewed Original ResearchDirect antiviral agentsChronic hepatitis C virus (HCV) infectionHepatitis C virus infectionQuality of lifeC virus infectionHealth-related qualitySuccessful treatmentVirus infectionAntiviral agentsChronic HCV infectionDAA treatmentExtrahepatic manifestationsHCV infectionLiver diseaseLong termLiver fibrosisObservational studyProfound negative impactNew drugsInfectionHRQLTreatmentAverage timePatientsDrugs
2020
SOFA score and short-term mortality in acute decompensated heart failure
Elias A, Agbarieh R, Saliba W, Khoury J, Bahouth F, Nashashibi J, Azzam Z. SOFA score and short-term mortality in acute decompensated heart failure. Scientific Reports 2020, 10: 20802. PMID: 33257739, PMCID: PMC7705654, DOI: 10.1038/s41598-020-77967-2.Peer-Reviewed Original ResearchConceptsAcute decompensated heart failureSequential Organ Function Assessment (SOFA) scoreShort-term mortalityDecompensated heart failureSOFA scoreHigh-risk patientsHospital mortalityRisk patientsHeart failureLife-threatening conditionCurve (AUC) of receiverFirst hospitalizationPrimary diagnosisRisk scorePatientsMortalityAssessment scoresStrict monitoringExcellent scoresCharacteristic curveHospitalizationScoresGood predictive accuracyProper managementSepsis
2019
Clinical characteristics and outcomes of patients with Escherichia coli in airway samples
Schneer S, Khoury J, Adir Y, Stein N, Mishan P, Ken‐Dror S, Weber G, Meler R, Khateeb A, Shteinberg M. Clinical characteristics and outcomes of patients with Escherichia coli in airway samples. The Clinical Respiratory Journal 2019, 14: 205-213. PMID: 31799802, DOI: 10.1111/crj.13116.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnti-Bacterial AgentsBronchiectasisCase-Control StudiesCommunity-Acquired InfectionsCross InfectionCystic FibrosisDrug Resistance, BacterialEscherichia coliEscherichia coli InfectionsFemaleHospitalizationHumansMaleMicrobial Sensitivity TestsMiddle AgedRespiratory Tract InfectionsSputumConceptsRespiratory secretionsResistant E. coliE. coli positive culturesResistant strainsMore hospitalization daysOutcomes of patientsGroup of patientsCommunity-acquired infectionsClinical characteristicsHospital daysPulmonary infectionHospitalization daysAmbulatory patientsPrevious hospitalizationAirway samplesPrognostic valueRespiratory pathogensCommon pathogensPositive culturesPatientsNosocomial pathogenAntibiotic classesAntimicrobial classesSecretionElevated mortalityThe association between fluconazole dose and MIC with mortality and persistence in candidemia
Ghanem-Zoubi N, Qasum M, Khoury J, Zorbavel D, Arnon M, Geffen Y, Paul M. The association between fluconazole dose and MIC with mortality and persistence in candidemia. European Journal Of Clinical Microbiology & Infectious Diseases 2019, 38: 1773-1780. PMID: 31197619, DOI: 10.1007/s10096-019-03611-1.Peer-Reviewed Original ResearchConceptsAUC24/MICClinical outcomesC. glabrata candidemiaComposite of mortalityExposure parametersLowest MIC valueSimilar non-significant differencesFluconazole doseFluconazole dosingPersistent candidemiaSingle centerMIC valuesClinical failureInclusion criteriaCandidemiaPatientsDay 14Non-significant differenceHigh MICsFluconazole MICsStudy periodMortalityCandida speciesMICC. glabrataRisk Factors for Non-Albicans Candidemia Focusing on Prior Antifungal and Immunosuppressive Therapy.
Ghanem-Zoubi N, Khoury J, Arnon M, Zorbavel D, Geffen Y, Paul M. Risk Factors for Non-Albicans Candidemia Focusing on Prior Antifungal and Immunosuppressive Therapy. Israel Medical Association Journal 2019, 21: 303-307. PMID: 31140219.Peer-Reviewed Original ResearchConceptsBlood stream infectionsSignificant risk factorsRisk factorsImmunosuppression therapyImmunosuppressive therapySignificant independent risk factorsRambam Health Care CampusCandida blood stream infectionEpisodes of candidemiaRetrospective cohort studyIndependent risk factorTertiary medical centerSubgroup of patientsBone marrow transplantationHealth Care CampusNon-albicans candidemiaNAC candidemiaNAC sppAdult patientsCohort studyMarrow transplantationClinical manifestationsMedical CenterCandidemiaPatients
2018
The association between treatment appropriateness according to EUCAST and CLSI breakpoints and mortality among patients with candidemia: a retrospective observational study
Ghanem-Zoubi N, Zorbavel D, Khoury J, Geffen Y, Qasum M, Predescu S, Paul M. The association between treatment appropriateness according to EUCAST and CLSI breakpoints and mortality among patients with candidemia: a retrospective observational study. European Journal Of Clinical Microbiology & Infectious Diseases 2018, 37: 2397-2404. PMID: 30284179, DOI: 10.1007/s10096-018-3389-1.Peer-Reviewed Original ResearchConceptsCLSI 2012Appropriate antifungal treatmentDefinitive treatmentOdds ratioAntifungal treatmentAntimicrobial Susceptibility Testing (EUCAST) breakpointsAppropriate definitive treatmentRetrospective observational studyAdjusted odds ratioAppropriate empirical treatmentBivariate logistic regressionCandidemia onsetCandidemia episodesEmpiric treatmentTreatment appropriatenessTertiary centerRetrospective studyCLSI breakpointsEmpirical treatmentObservational studyBreakpoint definitionPatientsResistance prevalenceMortalityLogistic regressionAwake endoscopic (esophageal) ultrasound using the endobronchial scope (EUS-B) for patients with high risk for sedation
Khoury J, Adir Y, Schneer S, Hakrush O, Abramovich A. Awake endoscopic (esophageal) ultrasound using the endobronchial scope (EUS-B) for patients with high risk for sedation. 2018, pa404. DOI: 10.1183/13993003.congress-2018.pa404.Peer-Reviewed Original ResearchUnexpected bleeding after Exenatide treatment: a causative relationship or a coincidence?
Khoury J, Andrawus E, Bishop B, Azzam Z. Unexpected bleeding after Exenatide treatment: a causative relationship or a coincidence? Endocrine Regulations 2018, 52: 159-162. PMID: 31517602, DOI: 10.2478/enr-2018-0020.Peer-Reviewed Original ResearchConceptsSpontaneous bleedingDiabetes mellitusType II diabetes mellitusYear old patientExenatide treatmentAntidiabetic medicationsExact pathophysiologyOlder patientsCoagulation profileSafety profilePatient historyAbnormal plateletsBleedingSide effectsMuscular bleedingExenatideCausative relationshipEndemic diseaseMellitusPatientsTreatmentFirst reportCurrent eraMedicationsPathophysiology
2017
Secondary antibiotic resistance of Helicobacter pylori isolates in Israeli children and adults
Khoury J, Geffen Y, Shaul R, Sholy H, Chowers Y, Saadi T. Secondary antibiotic resistance of Helicobacter pylori isolates in Israeli children and adults. Journal Of Global Antimicrobial Resistance 2017, 10: 182-185. PMID: 28732784, DOI: 10.1016/j.jgar.2017.05.017.Peer-Reviewed Original ResearchConceptsH. pylori culturePositive H. pylori culturePylori cultureTherapeutic regimensH. pyloriRambam Health Care CampusSecondary antibiotic resistanceHelicobacter pylori infectionHealth Care CampusAntibiotic resistanceH. pylori strainsHelicobacter pylori isolatesStandard therapyPylori infectionGastric biopsiesSecondary antimicrobial resistanceLEV resistancePylori isolatesPatientsAntimicrobial susceptibilityClarithromycinPylori strainsMetronidazoleAmoxicillinAntimicrobial resistance
2016
Severe Elevation of Liver Enzymes Does Not Necessarily Require Treatment Interruption in Patients Treated With a Combination of Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for HCV Infection
Saadi T, Khoury J. Severe Elevation of Liver Enzymes Does Not Necessarily Require Treatment Interruption in Patients Treated With a Combination of Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for HCV Infection. Journal Of Clinical Gastroenterology 2016, 50: 799. PMID: 27380458, DOI: 10.1097/mcg.0000000000000587.Commentaries, Editorials and LettersMeSH Keywords2-NaphthylamineAlanine TransaminaseAnilidesAntiviral AgentsAspartate AminotransferasesCarbamatesCyclopropanesDrug Therapy, CombinationFemaleHepatitis C, ChronicHumansLactams, MacrocyclicMacrocyclic CompoundsMiddle AgedProlineRibavirinRitonavirSulfonamidesUracilValineWithholding Treatment
2014
Alkaline phosphatase level change in patients with osteosarcoma: its role as a predictive factor of tumor necrosis and clinical outcome.
Khoury J, Ben-Arush M, Weintraub M, Waldman E, Futerman B, Vlodavsky E, Postovsky S. Alkaline phosphatase level change in patients with osteosarcoma: its role as a predictive factor of tumor necrosis and clinical outcome. Israel Medical Association Journal 2014, 16: 26-32. PMID: 24575501.Peer-Reviewed Original ResearchConceptsTumor necrosisBetter prognosisClinical outcomesPredictive factorsHistological responseBetter survivalSerum alkaline phosphatase levelsEvidence of diseaseSignificant predictive factorsAlkaline phosphatase levelsNeoadjuvant chemotherapyOverall survivalWorse survivalFemale patientsMedical filesOsteosarcoma patientsPatientsPhosphatase levelsSAP responseNecrosisFirst monthRespondersPredictive indicatorDiseaseSurvival